Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01574287Not ApplicableCompleted

Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas

Role: lead

NCT01808222Phase 2Completed

FACBC for Recurrent Prostate Cancer

Role: lead

NCT00562315Phase 2Completed

FACBC PET/CT for Recurrent Prostate Cancer

Role: lead

NCT00917865Phase 2Terminated

FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

Role: lead

All 4 trials loaded